PureTech’s LYT-200 Gains the US FDA’s Fast Track Designation for Treating Head and Neck Cancers
Shots:
- The US FDA has granted FTD to LYT-200, human IgG4 mAb targeting galectin-9, in addition with tislelizumab to treat recurrent/metastatic HNSCC
- The company’s LYT-200 is under the P-I/II trial as monotx. & combined with tislelizumab for advanced/metastatic solid tumors incl. HNSCC in which it demonstrated disease control, anti-tumor activity & a favorable safety profile across all cohorts
- LYT-200 is also being investigated in the P-Ib study as monotx. & in combination with venetoclax & hypomethylating agents for treating hematological malignancies such as AML & high-risk myelodysplastic syndrome in which it showed a favorable safety & tolerability profile as well as potential clinical activity
Ref: PureTech | Image: PureTech
Related News:- PureTech Founded Entity Akili Reports Investigator-Initiated Study Results of AKL-T01 for Systemic Lupus Erythematosus
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
